Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
about
The promise of neuroprotective agents in Parkinson's diseaseRivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neuronsProteomic analysis reveals late exercise effects on cardiac remodeling following myocardial infarction.Study of PTPC composition during apoptosis for identification of viral protein target.Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybridsMitochondrial apoptosis and the peripheral benzodiazepine receptor: a novel target for viral and pharmacological manipulationThe neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in ratsRasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.Hybrids: a new paradigm to treat Alzheimer's disease.Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease.TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements.Rasagiline in treatment of Parkinson's disease.Aβ impairs nicotinic regulation of inhibitory synaptic transmission and interneuron excitability in prefrontal cortex.Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.Dose-dependent effects of ladostigil on microglial activation and cognition in aged rats.Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.Anti-inflammatory effects of ladostigil and its metabolites in aged rat brain and in microglial cells.N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties.Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
P2860
Q21129436-F6712514-F0C3-444C-B75C-3B64F632E839Q28479242-CC530DE7-462D-4013-9C3A-B8DB262BBEC3Q34126907-C893EDE5-896C-4AB0-8666-CF116EABE2FBQ34307368-598357DE-CEFC-4870-AC6D-98AD0B9E5078Q34394212-CD03F628-75CF-4007-B969-61CD07040DF4Q34989649-CA73A206-7ECD-4598-BFBB-7EE028EB99D1Q35545032-5EBC89D7-A7C6-4FF5-8328-D164751609B6Q35738987-89986891-E5D6-4D86-8A30-1AA93E225431Q36177001-2AEFE96F-DE4E-499C-A987-0F46630E68CAQ36307876-0235007C-18B0-4529-BB79-2E8F01CAF273Q36349629-02C25577-F841-46AB-AE40-B26F1567CCE3Q36499640-D20FBB6C-D07A-4FEB-91F5-856B9A3D9A19Q37005143-C6A8AA99-17AD-4D98-9C19-0A957C4465E2Q37963572-FAED1BE8-0D46-489A-A866-5A72B024F816Q38066606-7F7D243D-A8EF-49D1-A6C1-B9699A0908CDQ38067297-ABC1EA4E-5291-4938-9584-6673F0B5DA37Q38447289-E02C3602-1CB3-44FE-A9AB-A6A33E80B6A5Q38578336-142831AA-5DF9-49E0-B14F-0012E6C6FA61Q38683819-590C3358-E8D7-45AC-AD11-E039257F910EQ38838153-D9D7807D-BDCD-477C-A7B9-6399EEE2FA20Q39315311-92A6581D-DB82-4200-8252-9069E24E10C4Q39367468-8B9089C2-2054-4F96-875F-C80C2ED712F0Q39681299-F368E2BF-4EA5-4BB5-9750-197546C3E3F2Q39694072-9EA301A7-CE58-4403-A7E6-712B9971705AQ45180137-0B792B84-9C59-4D40-96DE-4A822B6D6262Q45208978-5A4CEA4F-9FBC-45FC-95D1-21EE3B4F3CE9Q48594845-495321AA-82F3-47B8-A536-1068E82A8D16Q51733605-9E5A1B9E-792D-473F-9897-70479EB90CC6Q52734704-6F2CDA8D-880A-4C5F-8F34-2C17098E10AC
P2860
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Molecular basis of neuroprotec ...... e anti-Alzheimer drug TV3326 [
@nl
Molecular basis of neuroprotec ...... 5-YL)-ethyl methyl carbamate].
@ast
Molecular basis of neuroprotec ...... 5-YL)-ethyl methyl carbamate].
@en
type
label
Molecular basis of neuroprotec ...... e anti-Alzheimer drug TV3326 [
@nl
Molecular basis of neuroprotec ...... 5-YL)-ethyl methyl carbamate].
@ast
Molecular basis of neuroprotec ...... 5-YL)-ethyl methyl carbamate].
@en
prefLabel
Molecular basis of neuroprotec ...... e anti-Alzheimer drug TV3326 [
@nl
Molecular basis of neuroprotec ...... 5-YL)-ethyl methyl carbamate].
@ast
Molecular basis of neuroprotec ...... 5-YL)-ethyl methyl carbamate].
@en
P356
P1476
Molecular basis of neuroprotec ...... 5-YL)-ethyl methyl carbamate].
@en
P2093
Weinstock M
P2888
P304
P356
10.1023/A:1015131516649
P577
2001-12-01T00:00:00Z
P5875
P6179
1029285224